A regulation with respect to bioequivalence and invitro dissolution of solid oral dosage forms in USA and Japan is summarized and compared. Significant differences in various parameters like dissolution, biowaiver, inclusion-exclusion criteria of subjects in the clinical trials, statistical results were found between two systems. The regulatory experienced gained up to now is studied and compared.
Introduction
Dissolution study is critical parameter of pharmaceutical dosage forms. It is well recognized that invitro dissolution testing, whether in development relied upon to screen formulation during development and batch to batch quality control (FDA/ CDER, 1997). Current International regulatory authorities require that final quality judgment of oral dosage form be based on its invitro dissolution and invivo bioequivalence testing (Rani and Pargal, 2004) . Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. Bioequivalence (BE) studies are a major component of ANDAs (FDA/CDER, 2003) . They verify that the active ingredient in a generic drug product will be absorbed into the body to the same extent and at the same rate as its corresponding reference listed drug (RLD) product. The significance of BE studies is that when two pharmaceutically equivalent products are shown to be bioequivalent, they are judged to be therapeutically equivalent. Therapeutically equivalent products are expected to have the same safety and efficacy profiles, when administered under the conditions listed in the product labeling. This is the basis for the approval and use of generic drug products. The design, performance and evaluation of bioequivalence studies have received major attention from academia, the pharmaceutical industry and health authorities over the past two decades. In this article we would like to provide an overview regarding the invitro dissolution and invivo BE testing regulations of the USFDA and NIHS JAPAN. There are some difference between the regulations of invitro dissolution and invivo BE studies though both the countries have very stringent regulations.
Regulation for dissolution testing
Dissolution chapter in the United States pharmacopoeia (USP 30 Dissolution <711>) is harmonized with the corresponding text of the Japanese Pharmacopoeia (JP 15 th Edition). Pharmacopoeias of both the countries have studied and compared, some differences are highlighted below also given in Table  1 and Table 2 e. There are two types of the interpretations namely Interpretation 1 and Interpretation 2 under the heading 'Interpretation', in Japanese pharmacopoeia. Acceptance criteria given in the Interpretation 1 of Japanese Pharmacopoeia is same as that of given in the Acceptance Table 1 , Acceptance Table 2,  ISSN:1948-593X JBABM, an open access journal   Acceptance Table 3 and Acceptance Table 4 of USP. However, in the 'Interpretations 2' of Japanese Pharmacopoeia, NIHS Japan has given acceptance criteria for immediate release dosage forms, extended release dosage forms and delayed release dosage forms. Provided that 'interpretation 1' should be followed when Q value is specified in the individual monograph otherwise Japanese pharmacopoeia recommended 'Interpretation 2'. This type of acceptance criteria has not given in USP, but USP has given a procedure for pooled sample for immediate release dosage form. This procedure is applicable only for immediate release dosage form and for apparatus 1(Basket) and apparatus 2 (Paddle).
f. Separate guidance on dissolution study requirements and testing condition for the drug products containing acidic, neutral, basic, coated products and low solubility drugs is one of the unique character of Japanese BA/ BE guidance. Also there is difference in specification of testing solution, testing time as well as buffers.
Regulation of biowaiver

FDA SUPAC IR
The guidance FDA SUPAC IR (FDA/CDER 1997) was first document to establish a consistent and clear policy to establish scale up and post approval changes to immediate release product.FDA SUPAC IR 1995 allows qualification of several types of changes in following parameters: 1) Component and composition 2) Site changes 3) Batch changes 4) Manufacturing 5) Invitro dissolution 6) In vivo bioequivalence studies.
Guideline identifies three 'Level of changes' level 1(unlikely to have any detectable impact on formulation quality and performance), level 2(could have significant impact), level 3 (likely to have a significant impact) (Gupta et al., 2006) . Table 3 it can be concluded that. c) In level 2 can be qualified by in vitro dissolution release specification which is depends on the three cases shown in Table  3 .
With reference to
One caveat (Gupta et al., 2006) to this guideline Is, This guideline does not give the post approval changes of API containing narrow therapeutic indices drugs (NTI). Narrow therapeutic drug always requires the in vivo bioequivalence qualification testing on each post approval changes. However 21 CFR 320.33 (c) defines it as there is less than 2 fold difference in median lethal dose LD 50 and median effective dose ED 50 values, or have less than 2 fold difference in the minimum toxic concentration and minimum effective concentration of the drug in the blood.
FDA BCS 2000
The guidance FDA, BCS (2000) (FDA/CDER 2000) categorizes APIs in to four classes:
Class1: High solubility-high permeability.
Class2: Low solubility-high permeability.
Class3: High solubility-low permeability. Class4: Low solubility-low permeability.
FDA guideline allows biowaiver for the drug products with BCS class I API as it contain highly soluble and highly permeable drugs like antipyrine, caffeine, carbamazepine but guidance does not accept biowaiver for Class II, III and IV. In addition FDA has given set of requirements for drug product from such class.
1. Drug product must show rapid dissolution, i.e. not less than 85% labeled amount of the drug substance dissolved within 30 min in a volume of 900 ml or less in each of the following media: (1) of absorption of a highly soluble and highly permeable drug substance that is formulated in a rapidly dissolving IR product. This criterion is considered to be met when amount of excipients in drug product is same in that of FDA approved IR dosage form as give in the orange book.
3. For biowaiver, if drug is prodrug and its conversion to active drug is occurring after intestinal permeation then FDA recommends to measure its permeability.
In following cases Biowaiver are not applicable. 1. For Narrow therapeutic range drug 2. Products to be absorbed in oral cavity.
If the drug product complies all of the above conditions then calculation of dissolution of similarity (should be ≥ 50) is sufficient to qualify biowaiver.
FDA BA/BE 2003
FDA BA/BE 2003 (FDA/CDER, 2003) guidance is another option which give waiver of in vivo bioequivalence test under CFR 320.22 (d) (2) when different strengths are in proportionally similar in active and inactive ingredients to strength of the product. There are three conditions under which drug product can be considered as proportionally similar.
1. All active and inactive ingredients are in exactly same proportion between different strength.
2. If the sum of all differences in excipients between two formulation is within 10 % i.e. falls within level 2 of FDA SUPAC IR 1995 3. For high potency API (5 mg dose), when total weight of the strengths is same, same excipients are used and small difference in composition is compensated by one of the excipients.
Regulation in Japan
No biowaiver accepted under Japanese regulation. For the approval of any generic solid oral immediate release dosage form, in vivo bioequivalence study is compulsory.
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Two guidelines guideline produced by the NIHS which relates to Japanese BA-BE these are namely.
1.
Guideline for Bioequivalence Studies for Formulation Changes of Oral Solid Dosage Forms (NIHS Japan, 2000).
2.
Guideline Table  4 .
Though Japanese guidance addressing formulation changes seems thus to be aligned in several effects with guidance FDA SUPAC IR 1995, there are some differences as described below.
1. Level B-C in the Japanese guideline is corresponds with the FDA SUPAC IR 1995, levels 2-3. However Level D is specific to Japan allowing for a larger change for drug product. Though Level D and Level 3 have same specifications, Level D allows biowaiver only for the Non narrow therapeutic drugs, high solubility drugs and rapidly dissolving drugs.
2. In Japanese guidance, there is separate table on the coat versus coated materials. Total change for the Level B, Level C and Level D is 5%, 10% and 15% respectively, while in the FDA SUPAC IR 1995 guidance the change for the film coat is of 1% for the Level 1 and 2% for the Level 2.
3. Japanese guideline does not accept BCS. It is believed that the formulation changes may be altering the bioavailability of the dosage form rather than the solubility and permeability of the drug products. Also bioequivalence of most of the IR products is mainly assured by the dissolution testing in multiple media hence BCS classification (based on the solubility and permeability) is not important.
Number of subject and subject selection criteria
FDA BA/BE 2003 guidance and food effect BA/ fed BE guidance recommended minimum 12 number of subject (more than 18 yrs old) for invivo BE study. While Japanese guidance recommended total 20 number of the subjects to be included in the BE study. Also for add on study additional 10 subjects are recommended along with initial subjects (NIHS Japan, 2000) .
The inclusion and exclusion criteria are almost same for both the countries, While Japanese guidance given additional recommendation of inclusion of the subjects having low gastric acidity (Achlorhydric subjects) for the reference and test product having significant difference at around pH 6.8 or between pH 3 and pH 6.8 for the product containing basic drugs. However this rule is not applied for the enteric coated product.
Study
Regulation in US
FDA BA BE 2003 has given option of pilot study. Sponsor can carry out pilot study on small number of the subjects before proceeding to BE study and this study can be used to validate analytical methodology, optimize sample collection time interval and provide other information.
In the bioequivalence study, for food effect study FDA BA BE recommended that 
Food-Effect Bioavailability and Fed Bioequivalence Studies 2002
Guideline (FDA/CDER, 2002) recommended that Fed BE study is unnecessary for post approval changes in the dosage form where only in vivo re-documentation of BE recommended under fasting condition.
Recommendation for Test Meal (NIHS Japan, 2000)
General principle behind the design of test meal is to provide greatest effect on GI physiology so that systemic drug availability is affected maximally. A high fat and a high caloric meal is recommended as test meal for food effect BA study and Fed BE study. Fat should be 50 % of total caloric content of the meal and 800 to 1000 calories considered as high calories. As per US regulation meal should contain 150 calories of protein, 250 calories of carbohydrates and 500-600 calories of fat.
It is recommended that the sponsor should report the caloric breakdown of the test meal during the study and also given that sponsor should provide rationale for the breakdown. FDA food effect BA study and Fed BE guideline 2002 gives option to sponsor to choose meal of different combination of fat, carbohydrate and protein as given in guidance 'food effect BA and fed BE 2002' but guidance also recommends that sponsor should choose one of meal containing high fat and high calories.
For fasting study guideline recommended overnight fasting of 10 hrs and no food should be allowed for 4 hrs after dose. For fed treatment guideline recommended fasting of 10 hrs subject should start recommended meal in 30 min or less; however the drug product should be administered 30 after the start of meal.
Though Japanese regulation addressing type of the studies is aligned in same manner as that of the US regulations, there are some difference in the sample collection, test meal, dose administration etc. These are listed below:
1. FDA food effect BA and fed BE study guideline recommended that both fasting study and fed study is required for the drug product while Japanese guidance specifies condition under which fed study need to be carried out.
2. FDA BCS 2003 gave a very good option to the sponsor that is 'Pilot study'. This may be useful for the sponsor to validate analytical method, to assess the variability also to optimize sample collection intervals. For example in the modified re- 
Test meal and Energy of test meal
1. In NIHS (Japanese) guidance the low fat and high caloric food is recommended. The caloric content is approximately 700 kcal out of which not more than 20% (140 kcal) is derived from the fat ( 
Difference in statistical calculations and bioequivalence report submission between US FDA and NIHS Japan
Though the regulation addressing the statistical outcomes and parameters submitted in bioequivalence reports, between both the countries is aligned on same principles but there are some differences which are as follows: ii. Difference in the logarithmic values of AUC and C max of test and reference products are between [log 0.9, log1.11]
iii. Equivalent dissolution conditions of test and reference products.
Details to be submitted in bioequivalence report:
USFDA recommended following points in the bioequivalence report submission, Japanese guidance have not given these points in the guideline. a. Bioanalytical method validation information-LOD, recovery, LOQ, Precision study, stability study, dilution integrity. b. Formulation data: Cores and coating information c. Reanalysis of study samples with limit of quantification and reasons of reanalysis. d. Subject dropout information with reason provided with replaced subject information. e. Standard curve and QC data f. SOP's dealing with bioanalytical repeats of study samples.
Conclusion
It is our hope that, this review will provide an easy quick overview for comparing several parameters of the dissolution studies and bioequivalence regulations of the United States and Japan. It will also useful for the quick reference of the regional or scientific philosophy on their applicability We caution that the regulatory landscape is dynamic, and this review is no substitute for consultation with the full text of currently applicable guidances and regulations, or indeed for direct consultation with the Health Authorities when biowaivers are being considered as part of registrational strategy.
It is further hoped that continued research and scientific/regulatory dialog might lead to optimal and harmonized application of biowaiver principles in the interest of improved worldwide access to needed medicines. 
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